Navigation Links
Effective Vaccine for Leishmaniasis in the Pipeline

Leishmaniasis is a parasitic disease that kills about 60,000 people annually. It spreads by the bite of infected female sand flies. // Visceral leishmaniasis infects about 500,000 people annually mainly in India, Bangladesh, Nepal, Sudan and Brazil. The most common drugs to treat leishmaniasis have serious side effects and are expensive. Symptoms of visceral leishmaniasis include fever, weight loss, and abnormalities of the liver and spleen. As there is no effective vaccine for the visceral, or internal, form of leishmaniasis till date there is an increase in the death rate due to the disease. Peter H. Seeberger, Ph.D., of the Laboratory for Organic Chemistry at the Swiss Federal Institute of Technology (ETH) in Zurich developed a fundamentally new vaccine for the disease. The research team consisted of scientists from the Swiss Tropical Institute in Basel and Pevion Inc., a biotech company focusing on virosomal delivery systems.

The results of the research findings were reported in ACS Chemical Biology, one of 34 peer-reviewed journals published by the American Chemical Society, the world’s largest scientific society. Several leishmaniasis candidate vaccines are in various stages of development. The vaccine is a new genre of carbohydrate-based vaccines. Carbohydrates are chemical compounds that include sugar which are linked together. The vaccine is not only useful in humans but can be used to protect pets (dogs) against leishmaniasis. Carbohydrate vaccines are used in everyday medicine, including vaccines to immunize against meningitis and other bacterial infections, mainly in small children in the United States. Those vaccines use carbohydrates isolated from the actual bacteria responsible for the diseases.

The carbohydrates act as antigens, which stimulate the immune system to produce antibodies. But now synthetic carbohydrates are used as antigens in order to control the purity and composition and avoid possible contamination. But one major drawback with carbohydrate vaccines is the difficulty in getting them to produce a strong immune response. Vaccine manufacturers achieve this by adding a booster substance called adjuvant. Seeberger’s vaccine against leishmaniasis combines the delivery vehicle, immune-stimulating antigen and adjuvant into one package.

The delivery vehicle is an influenza virosome that is an empty envelope of the influenza virus. They contain none of the infectious genetic material of the flu viruses. The virosome also acts as an adjuvant, boosting the immune response of the vaccine. The antigen is a synthetic carbohydrate similar to substances on the surface of the leishmaniasis bacteria. Seeberger’s group is planning to test the vaccine on animals. WHO assigned a high priority to development of a leishmaniasis vaccine because of the huge human toll and the lack of any effective treatment.

'"/>




Related medicine news :

1. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
2. Inhaled Steroids Safe & Effective for Children with Asthma
3. ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer
4. Fluoride Found Effective in Osteoporosis
5. Aspirin and Warfarin Are Equally Effective for Stroke Prevention
6. Implantable Contact Lens Found Safe and Effective
7. Effective And Economical Agent For Anthrax
8. Stem Cell Transplants May Be Effective For MS Patients
9. Effective therapy for Huntingtons disease
10. Chemotherapy Effective for Bladder Cancer
11. Drug Effective for Vascular Dementia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics ... PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... of Morris F. Collen, a pioneer in the field of medical informatics, this prestigious ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... --  Divoti USA will engrave and process all ... the latest FDA requirements, which stipulates new criteria regarding medical device ... of Medical ID jewelry such as Medical ID Bracelets, can rest ... terms of the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving ...
(Date:10/11/2017)... Texas , Oct. 11, 2017  True ... services, has amplified its effort during National Breast ... about hereditary cancer risks. ... of Clinical Oncology calculated that more than 10 ... have inherited mutations in BRCA1 or BRCA2 and have ...
(Date:10/7/2017)...   Provista, a proven leader in the ... purchasing power, today announced a new resource area on ... is the online home for case studies, articles ... news releases, slideshows and events. ... resources at their fingertips, viewers can also watch short ...
Breaking Medicine Technology: